US-based Celldex Therapeutics, Inc. (Nasdaq: CLDX) announced the closing of an underwritten public offering of common stock, raising USD 345 million in gross proceeds to fund the continued clinical and preclinical development of its antibody-based pipeline targeting mast cell biology and inflammatory disease pathways.
The offering comprised 11,896,750 shares of common stock priced at USD 29.00 per share, with all shares sold by Celldex. The total share count includes the full exercise by the underwriters of their option to purchase an additional 1,551,750 shares, representing the standard 15% overallotment. No warrants were issued in connection with this transaction. Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor served as joint bookrunning managers for the offering. LifeSci Capital and H.C. Wainwright & Co. acted as co-lead managers.
Company overview and pipeline
Celldex Therapeutics is a clinical-stage biotechnology company headquartered in Hampton, New Jersey, focused on the development of antibody-based therapeutics at the intersection of mast cell biology and immune modulation. Its pipeline addresses severe inflammatory, allergic, and autoimmune diseases.